Phase II trial of 4'-epi-doxorubicin in advanced carcinoma of head and neck origin

Cancer Treat Rep. 1985 Jan;69(1):125-6.

Abstract

Thirty-one patients with advanced head and neck cancer were treated with 4'-epidoxorubicin. Three of 25 evaluable patients with squamous cell carcinoma and two of three with minor salivary gland carcinoma had partial remissions. Four patients received cumulative doses of 680-1270 mg/m2; none developed clinical heart failure.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Carcinoma, Squamous Cell / drug therapy*
  • Carcinoma, Squamous Cell / pathology
  • Doxorubicin / adverse effects
  • Doxorubicin / therapeutic use*
  • Drug Evaluation
  • Epirubicin
  • Female
  • Head and Neck Neoplasms / drug therapy*
  • Head and Neck Neoplasms / pathology
  • Humans
  • Leukocyte Count
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Platelet Count

Substances

  • Epirubicin
  • Doxorubicin